Recursion Pharmaceuticals
RXRX
RXRX
265 hedge funds and large institutions have $1.74B invested in Recursion Pharmaceuticals in 2024 Q3 according to their latest regulatory filings, with 44 funds opening new positions, 111 increasing their positions, 52 reducing their positions, and 45 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding in top 10
Funds holding in top 10: →
less first-time investments, than exits
New positions opened: | Existing positions closed:
less funds holding
Funds holding: →
8% less capital invested
Capital invested by funds: $1.89B → $1.74B (-$145M)
15.24% less ownership
Funds ownership: 109.44% → 94.2% (-15%)
42% less call options, than puts
Call options by funds: $11.4M | Put options by funds: $19.8M
Holders
265
Holding in Top 10
6
Calls
$11.4M
Puts
$19.8M
Top Buyers
| 1 | +$30.5M | |
| 2 | +$27.2M | |
| 3 | +$22.6M | |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$17.9M |
| 5 |
DM
Deerfield Management
New York
|
+$15.3M |
Top Sellers
| 1 | -$21.8M | |
| 2 | -$8.9M | |
| 3 | -$8.25M | |
| 4 |
PA
Perceptive Advisors
New York
|
-$5.77M |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$5.6M |